GLP-1 Statistics: Users, Prescriptions, Spend, Trial Results
The GLP-1 numbers people cite most, each with the page it comes from: trial weight loss, how many stop because of side effects, list and self-pay prices, Medicare rules and shortage dates.
- Statistics
- 55
- Topics
- Compounding, Coverage, Prices, Shortages, Side effects, Stopping, Trial results
| Topic | Statistic | Value |
|---|---|---|
| Trial results | In STEP 1, average weight loss was measured at 68 weeks with weekly Semaglutide 2.4 mg | 14.9% |
| Trial results | In OASIS 4, average weight loss was measured at 64 weeks for people taking the Wegovy pill daily at 25 mg | 13.6% |
| Trial results | Tirzepatide 5 mg given weekly in SURMOUNT-1 was linked to a mean weight loss over 72 weeks | 15% |
| Trial results | Tirzepatide 10 mg given weekly in SURMOUNT-1 was linked to a mean weight loss over 72 weeks | 19.5% |
| Trial results | Tirzepatide 15 mg given weekly in SURMOUNT-1 was linked to a mean weight loss over 72 weeks | 20.9% |
| Trial results | Tirzepatide 10 mg given weekly in SURMOUNT-2 was linked to a mean weight loss over 72 weeks | 12.8% |
| Trial results | Tirzepatide 15 mg given weekly in SURMOUNT-2 was linked to a mean weight loss over 72 weeks | 14.7% |
| Trial results | After 72 weeks of weekly Tirzepatide 10 or 15 mg (Zepbound), SURMOUNT-5 recorded mean weight loss | 20.2% |
| Trial results | SURMOUNT-5 recorded average weight loss across 72 weeks with Wegovy taken weekly using Semaglutide 1.7 mg or 2.4 mg | 13.7% |
| Trial results | In SCALE Obesity and Prediabetes, average weight loss was measured at 56 weeks with daily Liraglutide 3.0 mg | 7.4% |
| Trial results | Foundayo 5.5 mg given daily in ATTAIN-1 was linked to a mean weight loss over 72 weeks | 7.4% |
| Trial results | Foundayo 9 mg given daily in ATTAIN-1 was linked to a mean weight loss over 72 weeks | 8.3% |
| Trial results | Foundayo 17.2 mg given daily in ATTAIN-1 was linked to a mean weight loss over 72 weeks | 11.1% |
| Trial results | Foundayo 5.5 mg given daily in ATTAIN-2 was linked to a mean weight loss over 72 weeks | 5.1% |
| Trial results | Foundayo 9 mg given daily in ATTAIN-2 was linked to a mean weight loss over 72 weeks | 7% |
| Trial results | Foundayo 17.2 mg given daily in ATTAIN-2 was linked to a mean weight loss over 72 weeks | 9.6% |
| Trial results | Semaglutide 2.4 mg given weekly in STEP 2 was linked to a mean weight loss over 68 weeks | 9.6% |
| Trial results | Over 52 weeks in STEP-HFpEF, weekly Semaglutide 2.4 mg showed a mean weight loss | 13.3% |
| Stopping | Side effects led to stopping Wegovy in the label trials | 6.8% |
| Stopping | Side effects led to stopping Zepbound in the label trials | 6.7% |
| Stopping | Side effects led to stopping Saxenda in the label trials | 9.8% |
| Stopping | Side effects led to stopping Foundayo in the label trials | 8% |
| Side effects | At the highest dose, the label trial reported nausea with Ozempic | 20.3% |
| Side effects | At the highest dose, the label trial reported nausea with Wegovy | 44% |
| Side effects | At the highest dose, the label trial reported nausea with Rybelsus | 20% |
| Side effects | At the highest dose, the label trial reported nausea with Mounjaro | 18% |
| Side effects | At the highest dose, the label trial reported nausea with Zepbound | 28% |
| Side effects | At the highest dose, the label trial reported nausea with Saxenda | 39.3% |
| Side effects | At the highest dose, the label trial reported nausea with Victoza | 20% |
| Side effects | At the highest dose, the label trial reported nausea with Trulicity | 21.1% |
| Side effects | At the highest dose, the label trial reported nausea with Foundayo | 35% |
| Side effects | At the highest dose, the label trial reported nausea with Byetta | 44% |
| Prices | For Ozempic, the list price before insurance applies to each pen | $1,027.51 |
| Prices | For Wegovy, the list price before insurance applies to each month | $1,349.02 |
| Prices | Before insurance, the list price for Rybelsus is per 30 tablets (list price) | $1,027.51 |
| Prices | Before insurance, the Mounjaro list price applies to each fill (list price) | $1,112.16 |
| Prices | Before insurance, the Zepbound list price applies to each fill (list price) | 499 to 1,086 |
| Prices | Before insurance, the Foundayo list price applies to each month (list price) | $649 |
| Prices | Before insurance, the Trulicity list price applies to each fill (list price) | $1,006.93 |
| Prices | Before insurance, the Saxenda list price applies to each 5 pens (list price) | $1,349.02 |
| Prices | Before insurance, the Victoza list price applies to each 2 pens (list price) | $543.51 |
| Prices | Ozempic lowest self-pay price (per month (starting self-pay)) | $199 |
| Prices | Lowest self-pay price for Wegovy, for each month (pill, starting dose) | $149 |
| Prices | Zepbound lowest self-pay price (per month (starting self-pay)) | $299 |
| Prices | Foundayo lowest self-pay price (per month (starting self-pay)) | $149 |
| Coverage | Medicare GLP-1 Bridge copay per month | $50 |
| Coverage | Medicare GLP-1 Bridge: a qualifying BMI without any other condition | 35 BMI (no condition needed) |
| Coverage | The income limit set by Lilly Cares is a percentage of the federal poverty level | 300% |
| Shortages | Tirzepatide first listed in shortage | December 15, 2022 |
| Shortages | Tirzepatide shortage resolved | December 19, 2024 |
| Shortages | Semaglutide first listed in shortage | 2022-03 month |
| Shortages | Semaglutide shortage resolved | February 21, 2025 |
| Shortages | Liraglutide first listed in shortage | July 18, 2023 |
| Compounding | Compounded semaglutide adverse event reports submitted to the FDA | 990 reports (as of 2026-05-31) |
| Compounding | Compounded tirzepatide adverse event reports submitted to the FDA | 730 reports, more than (as of 2026-05-31) |
Download all 55 statistics as CSV
Half-life and weight loss overview
The number of days is the half-life: how long the body needs to remove half a dose. This comes from section 12.3 in each FDA label.
Body weight percentage. Trials use different doses and time periods, so check each result against the placebo listed with it on that drug's page.